MiNK Therapeutics, Inc. (INKT): Price and Financial Metrics


MiNK Therapeutics, Inc. (INKT): $2.24

0.03 (+1.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INKT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

INKT Stock Price Chart Interactive Chart >

Price chart for INKT

INKT Price/Volume Stats

Current price $2.24 52-week high $4.32
Prev. close $2.21 52-week low $1.09
Day low $2.21 Volume 8,150
Day high $2.34 Avg. volume 10,986
50-day MA $2.43 Dividend yield N/A
200-day MA $2.07 Market Cap 75.68M

MiNK Therapeutics, Inc. (INKT) Company Bio


MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.


INKT Latest News Stream


Event/Time News Detail
Loading, please wait...

INKT Latest Social Stream


Loading social stream, please wait...

View Full INKT Social Stream

Latest INKT News From Around the Web

Below are the latest news stories about MINK THERAPEUTICS INC that investors may wish to consider to help them evaluate INKT as an investment opportunity.

MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 18th, at 11:00 AM ET. Access

Yahoo | January 11, 2023

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2022 Earnings Call Transcript

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2022 Earnings Call Transcript November 6, 2022 Operator: Good morning, and welcome to MiNK Therapeutics’ Third Quarter 2022 Conference Call and Webcast. All participants will be in a listen-only mode until the question-and-answer session. Please note, this event is being recorded. If anyone has any objections, you may disconnect at […]

Yahoo | December 22, 2022

MiNK Therapeutics (INKT) Stock: Undervalued Given Platform''s Potential

MiNK Therapeutics reported positive results from two Phase 1 trials. Read why I think INKT stock is undervalued.

Seeking Alpha | December 5, 2022

MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference

NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 5 th Annual Evercore ISI HealthCONx Conference on Thursday December 1 st , at 4:45 PM ET.

GlobeNewswire | November 17, 2022

Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday

Gainers ShiftPixy, Inc. (NASDAQ: PIXY ) shares surged 56.6% to settle at $19.10 on Friday. Shares of several companies in the broader industrial space traded higher on continued hopes of softer Fed policy after CPI this week showed October inflation below estimates. Exela Technologies, Inc. (NASDAQ: XELA ) gained 50.3% to close at $0.2780. The company is expected to report Q3 results on November 14, 2022. uCloudlink Group Inc. (NASDAQ: UCL ) jumped 49.6% to close at $1.90. uCloudlink Group is expected to report Q3 financial results on November 16, 2022. Core Scientific, Inc. (NASDAQ: CORZ ) gained 44.3% to settle at $0.1981. Compass, Inc. (NYSE: COMP ) jumped 44% to close at $3.50. Compass posted a wider-than-expected loss for its third quarter, while sales topped estimates. Kaleyra, In...

Benzinga | November 14, 2022

Read More 'INKT' Stories Here

INKT Price Returns

1-mo 2.75%
3-mo 10.34%
6-mo 70.99%
1-year -22.22%
3-year N/A
5-year N/A
YTD -14.18%
2022 -41.48%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6336 seconds.